Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics.

ABSTRACT:

Background

The treatment of cancer during pregnancy remains challenging with knowledge gaps in drug dosage, safety, and efficacy due to the under-representation of this population in clinical trials. Our aim was to investigate physiological changes reported in both pregnancy and cancer populations into a PBPK modeling framework that allows for a more accurate estimation of PK changes in pregnant patients with cancer.

Methods

Paclitaxel and docetaxel were selected to validate a population model using clinical data from pregnant patients with cancer. The validated population model was subsequently used to predict the PK of acalabrutinib in pregnant patients with cancer.

Results

The Simcyp pregnancy population model reasonably predicted the PK of docetaxel in pregnant pa

SUBMITTER: Yang X 

PROVIDER: S-EPMC10748010 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature